Navigation Links
Healionics Corporation Completes Series A Financing
Date:1/29/2008

REDMOND, Wash., Jan. 29 /PRNewswire/ -- Healionics Corporation, a provider of tissue regeneration and device biointegration solutions to healthcare manufacturers, today announced that it has raised $1.7 million in a Series A financing. The financing was led by individual investors including Carl Lombardi, former CEO of SpaceLabs Medical and Sam Naficy, M.D., Medical Director of Naficy Plastic Surgery & Rejuvenation Center.

"We are pleased to secure this financing, which provides recognition of our technology platform and allows Healionics to continue expanding the potential of STAR materials to enhance current and next generation medical devices," said Rob Brown, Chief Executive Officer of Healionics. "These funds will be used specifically to scale up the STAR material manufacturing process, to expand and accelerate preclinical studies of STAR materials and to advance our business development activities."

Healionics' propriety STAR Material -- Sphere Templated Angiogenic Regenerative Material -- is specifically engineered to enhance biointegration and promote healing. Described as the 'Gore-Tex(TM) of biomaterials,' STAR is designed to enable the biocompatibility of a wide range of medical devices that are implanted into the body.

"Healionics has a very promising technology that offers widespread opportunities in a rapidly expanding cosmetic market," said Sam Naficy, M.D. "It is this versatility and expansiveness that make Healionics a very attractive business model, and I look forward to the future advancement of this Company."

Healionics was formed in March 2007. To date, Healionics has entered into multiple agreements for the advancement of its STAR(TM) material into various market applications including diabetes, wound care and infusion therapy.

About Healionics Corporation

Healionics is a privately held biomaterials company whose mission is to be the leading partner of tissue regeneration and device biointegratio
'/>"/>

SOURCE Healionics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Healionics Corporation Announces Partnership to Develop and Distribute STARcuff(TM)
2. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. BioElectronics Corporation Announces Singapore and Malaysia Sales
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
9. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
10. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... LUVOX(R) CR Approved and Launched - Screening C...al, PALO ALTO, Calif., May 13 Jazz,Pharmaceutica...l results for,the quarter ended March 31, 2008., ...8 were $14.6 million,compared to $14.1 million for...m oxybate oral solution) net sales for the first q...
...upport for Grassley-Kohl Bill Newest Addition to L... Agenda, INDIANAPOLIS, May 13 Today Eli Lilly a...the newly revised Physicians,Payments Sunshine Act...sley,(R-Iowa) and Herbert Kohl (D-Wisconsin). The ...y of payments to physicians by medical device,medi...
...AKE FOREST, Ill., May 13 Hospira, Inc.,(NYSE: HS...ion delivery,company, announced today that Barbara... board of directors. Bowles brings strong investme...p positions held at major,multinational consumer g...s. The addition of Bowles expands Hospira,s board ...
Other Biology Technology:Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 6Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 7Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 8Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians 2Lilly Backs Federal Legislation to Inform the Public on Payments to Physicians 3Hospira Expands Board of Directors 2
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2CCNY professor foresees rising Antarctic snowmelt 2Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 1Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 2Compressus Initiates Enterprise Workflow Management Implementation at Radiology Associates of Fox Valley 48037 3Senior Citizens Bureau Creates New Resourceful Divisions 48034 1Senior Citizens Bureau Creates New Resourceful Divisions 48034 2Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference 48033 1
...earch suggests that lowering cholesterol may block...t by Solomon et al, "Ezetimibe Is an Inhibitor of ...ue of The American Journal of Pathology . , High... heart disease, but may also contribute to cancer ...st common non-skin cancer in the United States, af...
... the human genome eight years ago, enormous progre.... Nevertheless, the function of most human genes i... in determining the function of a gene or protein ...undreds of other organisms that are experimentally...ted genes or proteins identified in these database...
...3, 2009 The legacy of nuclear weapons and nuclear...ment at dozens of sites across the United States a...anium. The uranium is transported through ground w...gy, uranium immobilization in contaminated ground ... of organic molecules known as electron donors to ...
Other Biology News:Lowering your cholesterol may decrease your risk of cancer 2Relationships in rank and file 2Relationships in rank and file 3Relationships in rank and file 4Patience pays off with methanol for uranium bioremediation 2
ImageQuant 300 from GE Healthcare, formerly Amersham Biosciences
Feline IL-12 / IL-23 p40, Unconjugated from R&D Systems
Rabbit Anti-ISOCITRATE DEHYDROGENASE Polyclonal Antibody, Unconjugated from AbD Serotec
... two highly efficient methods of identifying recom...consuming plasmid preparation. By using the large-...s to transfer partial colonies of E. coli bacteria...solutions provided by the kits and immediately run...
Biology Products: